In the Invited Commentary “Reforming the 340B Drug Pricing Program: Tradeoffs Between Hospital and Manufacturer Revenues” by Coukell and Dickson,1 there were several inaccuracies throughout the text, specifically in paragraphs 5, 6, 7, and 9, owing to the authors’ review of an earlier version of the accompanying Research Letter, on which they based their commentary. A letter of explanation2 describes the changes. This article has been corrected online.